| Recruiting | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder Major Depressive Disorder (MDD) | Phase 2 | 2026-01-19 |
| Recruiting | SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures Focal Onset Seizures | Phase 2 | 2025-07-30 |
| Recruiting | Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United Sta Parkinson Disease | — | 2025-03-31 |
| Recruiting | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures Focal Onset Seizures | Phase 2 | 2024-12-30 |
| Completed | Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood S Attention-Deficit/Hyperactivity Disorder | Phase 4 | 2024-03-25 |
| Recruiting | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD Attention-Deficit/Hyperactivity Disorder | Phase 4 | 2024-03-19 |
| Completed | Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lacta Healthy Lactating Women | Phase 4 | 2023-05-23 |
| Completed | An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus Tinnitus | Phase 2 | 2023-05-10 |
| Unknown | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy Epilepsy, Seizures, Epileptic | Phase 2 | 2023-02-07 |
| Terminated | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease Huntington's Disease | Phase 3 | 2022-12-14 |
| Completed | A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Du Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease | Phase 2 | 2022-11-29 |
| Completed | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment Parkinson Disease, Cognitive Dysfunction | Phase 2 | 2022-06-06 |
| Completed | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease Huntington Disease | Phase 2 | 2022-05-26 |
| Completed | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD Huntington's Disease | Phase 2 | 2022-01-26 |
| Unknown | Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Spasticity, Cerebrovascular Accident, Multiple Sclerosis | Phase 2 / Phase 3 | 2021-11-16 |
| Completed | Mass Balance Study of NV-5138 in Healthy Male Subjects Healthy Volunteers | Phase 1 | 2021-11-11 |
| Completed | Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult S Healthy Volunteer | EARLY_Phase 1 | 2021-10-19 |
| Completed | A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting Postpartum Depression | Phase 4 | 2021-10-08 |
| Completed | Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmaco Healthy Volunteer | Phase 1 | 2021-09-21 |
| Completed | Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 4 | 2021-07-27 |
| Completed | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Alzheimer Disease, Cognitive Dysfunction, Mild Dementia | Phase 2 | 2020-12-07 |
| Completed | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cogn Parkinson Disease, Cognitive Dysfunction | Phase 2 | 2020-07-31 |
| Terminated | Therapy for Migraine Prevention in Children 6-11 Years of Age Migraine Disorders, Headache Disorders | Phase 4 | 2020-07-14 |
| Completed | Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD Attention-Deficit/Hyperactivity Disorder | Phase 3 | 2020-01-23 |
| Unknown | Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Spasticity | Phase 2 / Phase 3 | 2019-12-17 |
| Completed | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 3 | 2019-11-20 |
| Withdrawn | Classroom Study of SPN-812 in Children With ADHD ADHD | Phase 3 | 2019-08-01 |
| Terminated | Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression | Phase 2 | 2019-05-30 |
| Completed | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Hunt Huntington Disease | Phase 1 | 2019-02-28 |
| Completed | A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Healthy Volunteer | Phase 1 | 2018-12-27 |
| Completed | A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Healthy Volunteer | Phase 1 | 2018-11-12 |
| Completed | A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketami Healthy Volunteer | Phase 1 | 2018-09-24 |
| Completed | A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Post Partum Depression | Phase 3 | 2018-09-07 |
| Completed | Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors Impulsive Aggression | — | 2018-08-10 |
| Terminated | Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment Attention Deficit Hyperactivity Disorder | Phase 3 | 2018-07-31 |
| Active Not Recruiting | BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures Focal Impaired Awareness Seizures | Phase 1 / Phase 2 | 2018-04-10 |
| Completed | Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) Idiopathic Parkinson Disease | — | 2017-11-30 |
| Completed | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD ADHD | Phase 3 | 2017-11-20 |
| Completed | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD ADHD | Phase 3 | 2017-11-02 |
| Completed | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD ADHD | Phase 3 | 2017-10-31 |
| Completed | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD ADHD | Phase 3 | 2017-10-20 |
| Completed | Bioavailability, Safety, and Tolerability of BIS-001 ER Epilepsy, Complex Partial | Phase 1 | 2017-05-22 |
| Completed | A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD Postpartum Depression | Phase 3 | 2016-08-01 |
| Completed | A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-P Postpartum Depression | Phase 3 | 2016-07-01 |
| Terminated | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4) Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | 2016-04-01 |
| Completed | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2) Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | 2016-02-16 |
| Active Not Recruiting | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) Attention-Deficit/Hyperactivity Disorder | Phase 3 | 2016-02-02 |
| Completed | Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 2 | 2016-02-01 |
| Completed | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1) Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | 2016-01-25 |
| Completed | A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression Severe Postpartum Depression | Phase 2 | 2015-12-15 |
| Completed | Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults Sialorrhea | Phase 3 | 2015-10-01 |
| Completed | A Study With SAGE-547 for Super-Refractory Status Epilepticus Super-Refractory Status Epilepticus | Phase 3 | 2015-06-01 |
| Completed | Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression Postpartum Depression | Phase 2 | 2015-01-07 |
| Completed | Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilep Super-refractory Status Epilepticus | Phase 1 / Phase 2 | 2014-03-21 |
| Completed | Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment Sialorrhea | Phase 3 | 2013-11-01 |
| Completed | Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M Impulsive Aggression Comorbid With ADHD | Phase 1 | 2013-11-01 |
| Completed | Open-Label, Extension Study to 810P202 Impulsive Aggression Comorbid With ADHD in Children | Phase 2 | 2011-09-01 |
| Completed | A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggres Impulsive Aggression Comorbid With ADHD | Phase 2 | 2011-06-01 |
| Completed | Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subj Epilepsy | Phase 1 / Phase 2 | 2011-01-01 |
| Completed | Evaluation of Immediate-Release Viloxazine in Adults With ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) | Phase 1 / Phase 2 | 2010-06-01 |
| Completed | A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM) Epilepsy | Phase 1 | 2010-06-01 |
| Completed | Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy Partial Epilepsy | Phase 3 | 2009-06-01 |
| Approved For Marketing | Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects Epilepsy | — | 2009-06-01 |
| Completed | Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjunctive Therapy in Pediatric Epileps Epilepsies, Partial | Phase 1 | 2009-06-01 |
| Completed | Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures Epilepsies, Partial | Phase 3 | 2008-11-01 |
| Completed | Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Prob Attention Deficit Disorder With Hyperactivity, Conduct Disorder | Phase 2 | 2008-10-21 |
| Approved For Marketing | Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression Postpartum Depression | — | — |
| No Longer Available | An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus Super-Refractory Status Epilepticus | — | — |